Geode Capital Management’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-76,235
Closed -$34K 4909
2022
Q4
$34K Hold
76,235
﹤0.01% 4690
2022
Q3
$36K Hold
76,235
﹤0.01% 4824
2022
Q2
$38K Buy
76,235
+27,451
+56% +$13.3K ﹤0.01% 4836
2022
Q1
$29K Buy
48,784
+8,616
+21% +$4.52K ﹤0.01% 4903
2021
Q4
$27K Buy
40,168
+19,856
+98% +$35.4K ﹤0.01% 4928
2021
Q3
$69K Sell
20,312
-7,942
-28% -$24.8K ﹤0.01% 4742
2021
Q2
$107K Sell
28,254
-30,448
-52% -$126K ﹤0.01% 4543
2021
Q1
$363K Buy
58,702
+10,926
+23% +$96.8K ﹤0.01% 3922
2020
Q4
$375K Buy
+47,776
New +$438K ﹤0.01% 3694

Other funds holding MTCR

Geode Capital Management's MTCR Position: Q1 2023 in Review

Geode Capital Management sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 76,235 shares — an estimated $34K sold.

Geode Capital Management first reported a position in MTCR in Q4 2020 and held it in 9 quarters. The position peaked at $375K in Q4 2020. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Geode Capital Management reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Geode Capital Management sold 76,235 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $34K.
  • Geode Capital Management first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
  • Geode Capital Management's Metacrine, Inc. Common Stock position peaked at $375K in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Geode Capital Management's 13F filing for Q1 2023, filed 15 May 2023.